Posted by Michael Wonder on 10 Jul 2024
Mirum Pharmaceuticals’ Livmarli approved in the European Union for patients with progressive familial intrahepatic cholestasis
8 July 2024 - Mirum Pharmaceuticals today announced that the European Commission has granted marketing authorization for Livmarli (maralixibat) oral solution for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
The approval follows a positive opinion by the CHMP which concluded that Livmarli in progressive familial intrahepatic cholestasis brings significant clinical benefit based on improved efficacy and a major contribution to patient care compared to the existing approved treatment for progressive familial intrahepatic cholestasis.
